Compare IDEXX Laboratories, Inc. (IDXX) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Lowe`s Companies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.7 (market cap $46.22B), while Lowe`s Companies Inc trades at $216.64 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 2.7× IDEXX Laboratories, Inc.'s market cap, and Lowe`s Companies Inc pays a 2.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LOW | |
|---|---|---|
Market Cap | $46.22B | $124.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $287.39 |
52-Week Low | $526.44 | $201.92 |
Enterprise Value | $47.12B | $165.81B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Lowe's (LOW) trades at $218.84, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company has beaten earnings estimates for the last three quarters, with Q2 2026 results expected on August 19. Revenue declined to $83.67 billion in 2025, but net income margin remained healthy at 7.51%. A $1.25 dividend is scheduled for payment on August 5, 2026.
The outlook is supported by strong analyst consensus, with a $257.06 price target implying 17% upside. Risks include high debt levels and competitive pressures. Earnings growth in the professional segment is a key catalyst, but macroeconomic headwinds could challenge DIY sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
